Literature DB >> 7841428

Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex.

L Trnka1, D Danková, E Svandová.   

Abstract

SETTING: In 1986, mass BCG vaccination of newborns was discontinued in an extensive territorial sample of neonates in the Czech Republic (30,000 infants annually). The non-vaccinated children have since been tuberculin tested at two-year intervals; those with continual or repeated intensive contact with animals in households or on farms were also tested with Mycobacterium avium intracellulare complex sensitin in addition to tuberculin.
OBJECTIVE: Within the frame work of the surveillance programme the incidence of infection and disease caused by M. avium intracellulare complex (M. avium complex) was evaluated and the protective effect of BCG vaccination analysed.
DESIGN: In 1986-93, out of 190,874 non-vaccinated children, 36 were found to be infected by M. avium complex; 27 of them developed disease, i.e. mycobacteriosis other than tuberculosis (MOTT).
RESULTS: The annual risk of infection with M. avium complex was 4.8/100,000 children per year, of whom 3.6/100,000 developed mycobacteriosis. 24 patients suffered from swelling of cervical lymph nodes, 2 of mediastinal lymph nodes and one child had the disease localized both in cervical and mediastinal lymph nodes. The disease was verified bacteriologically in 9 children. Most of the diseased children had impaired immunity; a marked skin reactivity of M. avium complex sensitin was present in all infected children. Animal sources infected by M. avium complex were detected in 5 cases. Another 14 children also had close contact with animals but without proven M. avium complex infection.
CONCLUSION: In non-BCG vaccinated children the incidence of lymphadenitis caused by M. avium complex was considerably higher than in vaccinated children. BCG cells possess antigenic determinants which confer protective immunity probably both against M. tuberculosis and against M. avium complex infections. It may thus be assumed that BCG vaccination protects both against pathogenic tubercle bacilli and M. avium complex. This should be taken into consideration before recommending discontinuation of mass BCG vaccination of newborns in areas with a high prevalence of M. avium complex infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841428     DOI: 10.1016/0962-8479(94)90080-9

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  21 in total

1.  Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection.

Authors:  E Martin; J A Triccas; A T Kamath; N Winter; W J Britton
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003.

Authors:  Theodore K Marras; Pamela Chedore; Alicia M Ying; Frances Jamieson
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

3.  Variable outcome of experimental interferon-gamma therapy of disseminated Bacillus Calmette-Guerin infection in two unrelated interleukin-12Rbeta1-deficient Slovakian children.

Authors:  Timo Ulrichs; Claire Fieschi; Eva Nevicka; Helmut Hahn; Martin Brezina; Stefan H E Kaufmann; Jean-Laurent Casanova; Klara Frecerova
Journal:  Eur J Pediatr       Date:  2005-01-05       Impact factor: 3.183

4.  Mycobacterial Infections of the Head and Neck.

Authors:  David C. Perlman; Ron D'Amico; Nadim Salomon
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

5.  Age-dependent humoral responses of children to mycobacterial antigens.

Authors:  M P Fairchok; J H Rouse; S L Morris
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

6.  Mycobacterium Avium Complex (MAC) Lung Disease in Two Inner City Community Hospitals: Recognition, Prevalence, Co-Infection with Mycobacterium Tuberculosis (MTB) and Pulmonary Function (PF) Improvements After Treatment.

Authors:  Zinobia Khan; Albert Miller; Moses Bachan; Joseph Donath
Journal:  Open Respir Med J       Date:  2010-08-08

Review 7.  Nontuberculous mycobacteria in respiratory tract infections, eastern Asia.

Authors:  Sami Simons; Jakko van Ingen; Po-Ren Hsueh; Nguyen Van Hung; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

8.  Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan.

Authors:  Shotaro Ide; Shigeki Nakamura; Yoshihiro Yamamoto; Yoshihisa Kohno; Yuichi Fukuda; Hideki Ikeda; Eisuke Sasaki; Katsunori Yanagihara; Yasuhito Higashiyama; Kohji Hashiguchi; Yoji Futsuki; Yuichi Inoue; Kiyoyasu Fukushima; Naofumi Suyama; Shigeru Kohno
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

9.  Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination.

Authors:  Marcela Parra; Xia Liu; Steven C Derrick; Amy Yang; Jinhua Tian; Kristopher Kolibab; Sanjai Kumar; Sheldon L Morris
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

10.  Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010.

Authors:  Theodore K Marras; David Mendelson; Alex Marchand-Austin; Kevin May; Frances B Jamieson
Journal:  Emerg Infect Dis       Date:  2013-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.